| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | paclitaxel | gCSI | pan-cancer | AAC | -0.0053 | 0.9 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.006 | 0.9 |
| mRNA | Sunitinib | FIMM | pan-cancer | AAC | -0.018 | 0.9 |
| mRNA | Cyclopamine | FIMM | pan-cancer | AAC | -0.015 | 0.9 |
| mRNA | FQI-1 | CTRPv2 | pan-cancer | AAC | -0.0044 | 0.9 |
| mRNA | AZ628 | GDSC1000 | pan-cancer | AAC | -0.0046 | 0.9 |
| mRNA | Vorinostat | gCSI | pan-cancer | AAC | -0.005 | 0.9 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0033 | 0.9 |
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | 0.0035 | 0.9 |
| mRNA | BIRB 0796 | GDSC1000 | pan-cancer | AAC | -0.0033 | 0.9 |